Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization

Sci Rep. 2022 Apr 25;12(1):6718. doi: 10.1038/s41598-022-10241-9.

Abstract

Myocardial injury after non-cardiac surgery (MINS) is common. We investigated the incidence and outcomes of MINS, and mechanistic underpinnings using pre-operative whole blood gene expression profiling in a prospective cohort study of individuals undergoing lower extremity revascularization (LER) for peripheral artery disease (PAD). Major adverse cardiovascular and limb events (MACLE) were defined as a composite of death, myocardial infarction, stroke, major lower extremity amputation or reoperation. Among 226 participants undergoing LER, MINS occurred in 53 (23.5%). Patients with MINS had a greater incidence of major adverse cardiovascular events (49.1% vs. 22.0%, adjusted HR 1.87, 95% CI 1.07-3.26) and MACLE (67.9% vs. 44.5%; adjusted HR 1.66, 95% CI 1.08-2.55) at median 20-month follow-up. Pre-operative whole blood transcriptome profiling of a nested matched MINS case-control cohort (n = 41) identified upregulation of pathways related to platelet alpha granules and coagulation in patients who subsequently developed MINS. Thrombospondin 1 (THBS1) mRNA expression was 60% higher at baseline in patients who later developed MINS, and was independently associated with long-term cardiovascular events in the Duke Catheterization Genetics biorepository cohort. In conclusion, pre-operative THBS1 mRNA expression is higher in patients who subsequently develop MINS and is associated with incident cardiovascular events. Pathways related to platelet activity and coagulation associated with MINS provide novel insights into mechanisms of myocardial injury.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Lower Extremity / blood supply
  • Peripheral Arterial Disease* / epidemiology
  • Peripheral Arterial Disease* / genetics
  • Peripheral Arterial Disease* / surgery
  • Prospective Studies
  • RNA, Messenger
  • Risk Factors
  • Transcriptome*

Substances

  • RNA, Messenger